The global market for CAR T-cell therapy in treating Non-Hodgkin's lymphoma is experiencing significant growth. This development is fueled by several factors, including rising prevalence of Non-Hodgkin's lymphoma, advancements in CAR T-cell therapy technology, and growing adoption by healthcare providers. The market is segmented based on factors su